Back to Trades
Total Value
$396.8K
Net $199.9K sold
Filing Date
Jul 23, 2026
1 transaction
Sales
$199.9K
1 transaction
Trade Summary
On Jul 21, 2026, Warren Eric, Chief Commercial Officer, sold $396.8K of Mineralys Therapeutics, Inc. (MLYS) across 1 transaction. The filing covers Common Stock and reflects net selling of $199.9K. Reported prices ranged from $13.24 to $26.87. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- Mineralys Therapeutics, Inc.
- Ticker Symbol
- MLYS
- CIK
- 0001933414
Insider Information
- Name
- Warren Eric
- Role
- Chief Commercial Officer
- Location
- RADNOR, PA
Filing Details
- Filing Date
- Jul 23, 2026
- Transaction Date
- Jul 21, 2026
- Accession Number
- 0001916048-26-000009
- Form Type
- 4
- Net Trading Amount
- -$199.9K
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Jul 21, 2026 | Common Stock | 7,438 | $13.24 | Exercise | $98.5K |
| Jul 21, 2026 | Common Stock | 7,438 | $26.87 | Sale | $199.9K |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Jul 21, 2026 | MLYS derivative | 7,438 | $13.24 | Exercise | $98.5K |
Want live alerts when Warren Eric trades again?
Download Insider Trades to track MLYS, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.
- (F2)The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.53 to $27.09. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
- (F3)The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.